|
Selonsertib
|
DB14916 |
[Selonsertib is under investigation in clinical trial NCT03053050 (Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis).] |
|
CODA-001
|
DB14915 |
[CODA-001 is under investigation in clinical trial NCT01165450 (Efficacy and Safety Study of Nexagon for Persistent Corneal Epithelial Defects).] |
|
Branaplam
|
DB14918 |
[Branaplam is under investigation in clinical trial NCT02268552 (An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)).] |
|
Ceralasertib
|
DB14917 |
[Ceralasertib is under investigation in clinical trial NCT03682289 (Phase II Trial of AZD6738 Alone and in Combination With Olaparib).] |
|
Pegvorhyaluronidase alfa
|
DB14912 |
[Pegvorhyaluronidase alfa is under investigation in clinical trial NCT02241187 (Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection).] |
|
Risuteganib
|
DB14911 |
[Risuteganib is under investigation in clinical trial NCT02348918 (Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema).] |
|
Flortaucipir F-18
|
DB14914 |
[Flortaucipir F-18 is under investigation in clinical trial NCT02278367 (Clinical Evaluation of 18F-AV-1451).] |
|
5-methyl-2'-fluoroarauracil F-18
|
DB14913 |
[5-methyl-2'-fluoroarauracil F-18 is under investigation in clinical trial NCT02809690 (18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer).] |
|
Mirikizumab
|
DB14910 |
[Mirikizumab is under investigation in clinical trial NCT03053622 (A Study of Mirikizumab (LY3074828) Injection in Healthy Participants).] |
|
K201
|
DB02929 |
|
|
Heptanoic Acid
|
DB02938 |
|
|
Tazobactam
|
DB01606 |
[Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms. It is combined with [Piperacillin] and [Ceftolozane] for the treatment of a variety of bacterial infections.
Piperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014[FDA label], providing wider antibacterial coverage for gram-negative infections. In June 2019, ceftolozane-tazobactam was approved by the FDA for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, which are significant causes of morbidity and mortality in hospitalized patients.[L6673]] |
|
Pivmecillinam
|
DB01605 |
[Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin. [PubChem]] |
|
4-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Butyric Acid
|
DB02936 |
|
|
Periciazine
|
DB01608 |
[Periciazine is a phenothiazine of the piperidine group. It has been shown to reduce pathologic arousal and affective tension in some psychotic patients, while the symptoms of abnormal mental integration are relatively unaffected. It is a sedative phenothiazine with weak antipsychotic properties. It also has adrenolytic, anticholinergic, metabolic and endocrine effects and an action on the extrapyramidal system. It is used as an adjunctive medication in some psychotic patients, for the control of residual prevailing hostility, impulsiveness and aggressiveness. Pericyazine, like other phenothiazines, is presumed to act principally in the subcortical areas, by producing what has been described as a central adrenergic blockade.] |
|
Gamma-Arsono-Beta, Gamma-Methyleneadenosine-5'-Diphosphate
|
DB02937 |
[Adenylic acid. Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. [PubChem]] |
|
Ticarcillin
|
DB01607 |
[An antibiotic derived from penicillin similar to carbenicillin in action.] |
|
9-(6-deoxy-alpha-L-talofuranosyl)-6-methylpurine
|
DB02934 |
|
|
Bacampicillin
|
DB01602 |
[Bacampicillin is a prodrug of ampicillin and is microbiologically inactive. It is absorbed following oral administration. During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal action through the inhibition of the biosynthesis of cell wall mucopeptides. It is used to cure infection of upper and lower respiratory tract; skin and soft tissue; urinary tract and acute uncomplicated gonococcal urethritis etc.] |
|
Diglyme
|
DB02935 |
|
